From gold and uranium to biotech and fintech, Zacks SCR highlights our analysts' best ideas for 2026: buff.ly/gewy0WC

#TRX #SBC #CBAT #TNXP #DYLLF #HITI #BGL #RADX

Liminal Space, by Radx from the album Reverse Acceleration of Dragons

🇺🇦 #NowPlaying on #KEXP's #Expansions

Radx:
🎵 Liminal Space

#Radx

▶️ 🪄 Automagic 🔊 show 📻 playlist on Spotify

▶️ Song/Cover on #Bandcamp:

Calm Vortex, by Radx from the album Reverse Acceleration of Dragons

🇺🇦 #NowPlaying on #KEXP's #VarietyMix

Radx:
🎵 Calm Vortex

#Radx

▶️ 🪄 Automagic 🔊 show 📻 playlist on Spotify

▶️ Song/Cover on #Bandcamp:

#RADX Interim Readout Achieves 92% Concordance buff.ly/QksaEaX #radiopharmaceuticals #cancer #oncology

Most searched small-cap stocks, Mon Dec 15th - #QUBT #KYTX #NVTS #JBLU #CLYM #RR #BEAT #BTBT #RADX #DNN #ARTV #BITF #MIST #PLUG #BBAI #USAR #TLRY #ONDS #IRBT #CLSK - More: crystalequityresearch.com/most-searche... - #smallcap

Small-cap stocks gapping up in trading, Mon Dec 15th - #UAG #RADX #MASK #QIPT #KYTX #KVHI #IMNM #ARTV - More: crystalequityresearch.com/trade-alerts... - #smallcap

📢 Stocks Trending NOW: #IRBT #TSLA #OCG #RADX #MIST #NOW #AMCI #CGC #KYTX #IMNM

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases Radiopharm Theranostics (ASX:RADX) reported interim Phase 2b imaging results for RAD 101 in brain metastases showing 92% concordance (11/12 patients) with MRI and selective tumor uptake on PET imaging.The company noted 50% trial enrollment, U.S. FDA Fast Track designation for RAD 101, and cited an independent U.S. market opportunity estimate of $500M+ annually. Management plans a webinar on Dec 15–16, 2025 and stated a goal to start a pivotal study by end of 2026.

#RADX Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

www.stocktitan.net/news/RADX/radiopharm-the...

#RSNA25 #RadX I am sure many of you gave b4 #HCWvsHunger started. Pls participate in challenge today by gathering old receipts & donating just another $50. Then enter your total for team #DiagnoseAndTreats Add #SNAPMatch!
It’s #GivingTuesday and our last chance to do good and win $20K !!!

#RSNA25 #RadX #Radiology team #DiagnoseAndTreats we are in the lead but do not not sleep on the #KidVengers
In the blink of an eye or shake of a baby rattle they will outraise us.
www.feedthechildren.org
8X match for your donation so do it now & log here hcwvshunger.org/how-to-donate/ #HCWvsHunger

a black background with colorful letters that say we 're all in this together ALT: a black background with colorful letters that say we 're all in this together

He is here with us !! #PathX and #OncX are together with #RadX as #DiagnoseAndTreats !

Who repping like us ? Who they came to see ? Team #DiagnoseAndTreats !! #RadX
6pm tonight #HCWvsHunger . Get ready to empty your wallets for food banks. Turn notifications on now please !

#DiagnoseAndTreats #RadX #OncX #RadOnc #PathX #HCWvsHunger
We play to win !!!

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer Radiopharm Theranostics (ASX:RADX) received Bellberry Human Research Ethics Committee approval on November 18, 2025 to start a First‑In‑Human Phase 1 trial of RAD 402, an anti‑KLK3 monoclonal antibody radiolabelled with 161Tb for metastatic or locally advanced prostate cancer.Preclinical biodistribution in mouse xenografts showed strong tumour targeting, limited bone and marrow uptake, and hepatic excretion. Radiopharm has supply agreements with Terthera (2022) for 161Tb production and Cyclotek (2025) for radiolabelling RAD 402, supporting trial initiation.

#RADX Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

www.stocktitan.net/news/RADX/radiopharm-the...

#RADX Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

www.stocktitan.net/news/RADX/radiopharm-the...

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 Radiopharm Theranostics (NASDAQ: RADX) announced on Nov 12, 2025 that enrollment of the second cohort is complete in the open-label Phase 0/1 trial of 177Lu-RAD204 in PD-L1 positive advanced cancers.The Data Safety Monitoring Committee approved escalation to a higher dose of 90 mCi for the Third Cohort. The first two cohorts showed tumor uptake and a favourable safety profile. The basket trial includes NSCLC, SCLC, TNBC, cutaneous melanoma, HNSCC and endometrial cancer and will continue to collect safety, biodistribution, dosimetry and preliminary anti-tumour data.

#RADX Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

www.stocktitan.net/news/RADX/radiopharm-the...

#RADX: Program and Financial Updates buff.ly/wO3mdQy

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs Radiopharm Theranostics (NASDAQ: RADX) reported positive early clinical data across four radiopharmaceutical programs and outlined near-term milestones through 2025–2026. Key updates: RAD 101 Phase 2b (n=30) has enrolled 12 patients with uptake seen in first three brain metastasis patients; topline Phase 2 expected H1 2026 and enrollment completion targeted Q1 2026. RAD 202 Phase 1 HEAT trial advanced to 75mCi after favorable DSMC review; cohort data from first three patients show significant HER2 tumor uptake with no drug-related adverse events; cohort 2 data expected by year-end 2025. RAD 204 Phase 1 showed tumor uptake and 2/3 patients with 5.5-month stable disease at 30mCi; dose escalation under DSMC review. RAD 301 Phase 1 imaging in PDAC (6/9 dosed) supported move to Phase 2 loco-regional study.

#RADX Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

www.stocktitan.net/news/RADX/radiopharm-the...

Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan RAD has received firm commitments for a A$35 million capital raising via an institutional private placement to new Australian and international institutional and sophisticated investors at A$0.03 per ordinary share Lantheus continues support as strategic investor with A$7.6 million investment in

#RADX Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

www.stocktitan.net/news/RADX/radiopharm-the...

#RADX: RAD101: Imaging Recurring Brain Metastases buff.ly/GurIN7F

#RADX: Prostate Cancer KOL Summary buff.ly/BnMw50w

Heavenly Shepherd of Silence, by Radx from the album Reverse Acceleration of Dragons

🇺🇦 #NowPlaying on #KEXP's #PacificNotions

Radx:
🎵 Heavenly Shepherd of Silence

#Radx

▶️ 🪄 Automagic 🔊 show 📻 playlist on Spotify

▶️ Song/Cover on #Bandcamp:

#RADX: July 2025 Update buff.ly/kR8Jr7g

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update Radiopharm Theranostics (NASDAQ: RADX), a clinical-stage biopharmaceutical company, reported significant progress across its radiopharmaceutical pipeline for FY2025. Key developments include FDA Fast Track Designation for RAD101 for brain metastases treatment differentiation, positive DSMC recommendation for RAD204 dose escalation to 60mCi, and advancement in the Phase 1 'HEAT' trial of RAD202 for HER2-positive tumors.The company maintains a strong financial position with cash balance of $29.12 million, up from $18.58 million year-over-year, providing runway through mid-2026. Notable achievements include IND clearance for RV-01, strategic supply agreements with ITM and Cyclotek for radioisotopes, and progression across multiple clinical trials with data readouts expected in H2 2025.

#RADX Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

www.stocktitan.net/news/RADX/radiopharm-the...

FDA Greenlight: Revolutionary Cancer Drug Betabart Heads to First Human Trials, Targets Aggressive Tumors Novel radiopharmaceutical shows promising preclinical results in targeting aggressive solid tumors. First-in-human trials set for Q4 2025. See breakthrough potential.

#RADX Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

www.stocktitan.net/news/RADX/radiopharm-the...

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia Radiopharm Theranostics (NASDAQ:RADX) has signed a clinical supply agreement with Cyclotek for the production of ¹⁶¹Tb-labeled RAD 402 for an upcoming Phase 1 clinical trial in prostate cancer. RAD 402, an anti-KLK3 monoclonal antibody radiotherapeutic, targets KLK3 which is highly expressed in prostate tissue with limited expression elsewhere.The agreement marks a crucial step toward initiating the first company-sponsored Phase I trial using Terbium-161 in prostate cancer, scheduled for 2H 2025. The preclinical data package is complete, showing safety and promising biodistribution. Notably, ¹⁶¹Tb offers potential advantages over ¹⁷⁷Lu through additional Auger and conversion electrons alongside β-radiation, potentially improving antitumoral therapeutic efficacy.

#RADX Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

www.stocktitan.net/news/RADX/radiopharm-the...

FDA Fast-Tracks Revolutionary Brain Cancer Diagnostic: Radiopharm's RAD101 Targets 300,000 Patient Market Novel imaging technology aims to revolutionize brain metastases diagnosis. Phase 2 trial targets 300K annual US patients. See upcoming H2 2025 results.

#RADX Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

www.stocktitan.net/news/RADX/radiopharm-the...

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors Phase 1 1 First-In-Human study designed to assess safety , tolerability , right dose for Phase 2 and early signs of efficacy of 177Lu-RAD20 2 in individuals with advanced HER2-positive solid tumors Previous clinical proof-of concept data 2 for targeting HER-2 demonstrated the safety and

#RADX Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

www.stocktitan.net/news/RADX/radiopharm-the...

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake Radiopharm Theranostics (RADX) reported favorable preclinical data for its Lu177-B7H3-monoclonal antibody RV01, showing promising biodistribution and high tumor uptake. The therapy, developed with MD Anderson Cancer Center, targets B7-H3 protein expressed in solid tumors. Key advantages include a shorter half-life of 1-2 days compared to traditional mAbs' week-long half-life, and liver excretion rather than kidney elimination, potentially reducing toxicity risks. The data completes the preclinical package required for IND submission to the FDA in mid-2025, with Phase 1 basket study initiation planned for Q4 2025. Previous studies showed complete regression of solid tumors and evidence of immune system stimulation.

#RADX Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

www.stocktitan.net/news/RADX/radiopharm-the...

Strategic Partnership Powers Next-Gen Cancer Treatments: Radiopharm Locks Critical Lutetium-177 Supply for 3 Clinical Programs Radiopharm partners with ITM for advanced radiopharmaceutical cancer treatments. Supply agreement covers three clinical programs targeting solid tumors. Learn more.

#RADX ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

www.stocktitan.net/news/RADX/itm-and-radiop...